MedTrace Logo

Systematically Assessing Effects of Colored Light on Humans With a Multi-modal Approach (Substudy 5 of 7)

NCT02919189 · Status: NOT_YET_RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 50

Last updated 2026-01-14

No results posted yet for this study

Summary

NOTE: This is the fifth of in total 7 sub-studies related to the Ethics Committee of the Canton of Bern Ref. No. KEK-BE 2016-00674. This sub-study includes 50 participants and 8 arms, in total 350 participants will be assessed in all 7 sub-studies.

General study information: This is a randomized, cross-over, quantitative study, which investigates physiological variables, mood, and affect of healthy participants in response to colored light exposure. The Participants take part in 5-8 arms and are exposed to colored light only, or are additionally asked to solve cognitive tasks during the colored light exposure. Primary aim is to measure the change in several physiological variables, mood, and affect during colored light exposure of 15 or 45 minutes. The risk for the participants is negligible and comparable to the risk during daily life.

Conditions

  • Exposure to Man-made Visible Light

Interventions

OTHER

Visible light exposure

Subjects will be exposed to visible colored light for 15 minutes. The visible light will be generated by fluorescent light lamps.

Sponsors & Collaborators

  • University of Bern

    lead OTHER

Principal Investigators

  • Ursula Wolf, Prof. Dr. · University of Bern

Study Design

Allocation
RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
SINGLE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
50 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2027-12-01
Primary Completion
2028-07-31
Completion
2029-07-31

Countries

  • Switzerland

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02919189 on ClinicalTrials.gov